Unique ID issued by UMIN | UMIN000024234 |
---|---|
Receipt number | R000027907 |
Scientific Title | Nocturia QOL evaluation in OAB patients treated with Oxybutinin & Mirabegron study |
Date of disclosure of the study information | 2016/10/01 |
Last modified on | 2023/10/17 18:49:34 |
Nocturia QOL evaluation in OAB patients treated with Oxybutinin & Mirabegron study
NEOXY study
Nocturia QOL evaluation in OAB patients treated with Oxybutinin & Mirabegron study
NEOXY study
Japan |
overactive bladder
Urology |
Others
NO
The effect of oxybutynin tape for nocturia and sleep quality is evaluated in overactive bladder patients with nocturia, setting as a reference selective beta-3 adrenergic receptor agonist Mirabegron.
Efficacy
N-QOL score
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
Arm of oxybutynin tape 73.5mg per one day for 8 weeks.
Arm of mirabegron 50mg per one day for 8 weeks.
20 | years-old | <= |
Not applicable |
Female
20 years of age or older of overactive bladder female patients with nocturia symptoms.
(1) Patients in the study drug administration proposed site with a skin disease and skin abnormalities.
(2) Patients with residual urine volume greater than 100mL.
(3) Patients with a difficulty in going to the bathroom without the assistance.
(4) Patients with a history of hypersensitivity of Oxybutynin hydrochloride or Mirabegron.
(5) Patients receiving flecainide acetate or propafenone hydrochloride.
(6) Patients with severe blood, liver, kidney disease and severe arrhythmia, suffering from cardiovascular diseases such as congestive heart failure.
(7) Patients with hypokalemia (less than 3.5mEq / L).
(8) Patients with paralytic ileus, ulcerative colitis, stomach atony, patients suffering from gastrointestinal diseases, such as bowel atony.
(9) Patients with Parkinson's syndrome, dementia, suffering from psychiatric and neurological disorders or cerebrovascular disorders such as myasthenia gravis.
(10) Patients with a glaucoma.
(11) Patients with a hyperthyroidism.
(12) Patients with malignant tumors.
(13) Pregnant patients, patients in lactating, and patients want to become pregnant during test period.
(14) Patients who participated in the other interventions tested within 16 weeks prior to study drug administration.
(15) Other, patient that investigators or test sharing doctor was ineligible as a subject of the present study.
120
1st name | |
Middle name | |
Last name | Osamu Ishizuka |
Department of Urology, school of medicine, Shinshu university
Urology
3-1-1 Asahi, Matsumoto, Nagano, Japan
+81263-35-4600
yokoso1046@shinshu-u.ac.jp
1st name | |
Middle name | |
Last name | Toshiro Suzuki |
Department of Urology, school of medicine, Shinshu university
Urology
3-1-1 Asahi, Matsumoto, Nagano, Japan
+81263-35-4600
yokoso1046@shinshu-u.ac.jp
Department of Urology, school of medicine, Shinshu university
Hisamitsu Pharmaceutical Co.,Inc
Profit organization
NO
2016 | Year | 10 | Month | 01 | Day |
Unpublished
Completed
2016 | Year | 09 | Month | 05 | Day |
2016 | Year | 09 | Month | 05 | Day |
2016 | Year | 10 | Month | 03 | Day |
2017 | Year | 09 | Month | 30 | Day |
2018 | Year | 03 | Month | 31 | Day |
2016 | Year | 09 | Month | 30 | Day |
2023 | Year | 10 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027907
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |